Inactive Instrument

Novartis AG Share Price Xetra

Equities

NOT

CH0012005267

Pharmaceuticals

Financials

Sales 2024 * 48.96B 45.44B 3,912B Sales 2025 * 50.79B 47.14B 4,058B Capitalization 203B 189B 16,255B
Net income 2024 * 10.5B 9.74B 839B Net income 2025 * 12.07B 11.2B 965B EV / Sales 2024 * 4.42 x
Net Debt 2024 * 12.88B 11.95B 1,029B Net Debt 2025 * 11.28B 10.47B 901B EV / Sales 2025 * 4.23 x
P/E ratio 2024 *
19.7 x
P/E ratio 2025 *
16.9 x
Employees 76,057
Yield 2024 *
3.62%
Yield 2025 *
3.76%
Free-Float 85.22%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer 48 31/12/04
Director of Finance/CFO 59 31/12/02
Chief Tech/Sci/R&D Officer 62 15/05/22
Members of the board TitleAgeSince
Director/Board Member 62 31/12/12
Director/Board Member 65 27/02/20
Chairman 68 31/12/12
More insiders
Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales (excluding discontinued operations) break down by therapeutic area as follows: - oncology (29.9%); - immunology (17.2%); - cardiovascular, renal and metabolic diseases (14.1%); - neuroscience (8.9%). The remaining net sales (29.9%) are from contract manufacturing of pharmaceutical products. At the end of 2023, Novartis AG had 33 production sites worldwide. Net sales are distributed geographically as follows: Europe (33%), the United States (39.5%), Asia/Africa/Australasia (20.5%), Canada and Latin America (7%).
More about the company